天冬酰胺酶
天冬酰胺
谷氨酰胺
自噬
天冬酰胺合成酶
谷氨酰胺酶
酶
癌症研究
生物
白血病
药理学
生物化学
细胞凋亡
免疫学
淋巴细胞白血病
氨基酸
作者
R. Sindhu,H. K. Manonmani
出处
期刊:Anti-cancer Agents in Medicinal Chemistry
[Bentham Science]
日期:2022-08-01
卷期号:22 (13): 2393-2410
被引量:1
标识
DOI:10.2174/1871520622666220106103336
摘要
Microbial L-asparaginase is the most effective first-line therapeutic used in the treatment protocols of paediatric and adult leukemia. Leukemic cell's auxotrophy for L-asparagine is exploited as a therapeutic strategy to mediate cell death through metabolic blockade of L-asparagine using L-asparaginase. Escherichia coli and Erwinia chrysanthemi serve as the major enzyme deriving sources accepted in clinical practise and the enzyme has bestowed improvements in patient outcomes over the last 40 years. However, an array of side effects generated by the native enzymes due to glutamine co-catalysis and short serum stays augmenting frequent dosages, intended a therapeutic switch towards the development of biobetter alternatives for the enzyme including the formulations resulting in sustained local depletion of L-asparagine. In addition, the treatment with L-asparaginase in few cancer types has proven to elicit drug-induced cytoprotective autophagy mechanisms and therefore warrants concern. Although the off-target glutamine hydrolysis has been viewed in contributing the drug-induced secondary responses in cells deficient with asparagine synthetase machinery, the beneficial role of glutaminase-asparaginase in proliferative regulation of asparagine prototrophic cells has been looked forward. The current review provides an overview on the enzyme's clinical applications in leukemia and possible therapeutic implications in other solid tumours, recent advancements in drug formulations, and discusses the aspects of two-sided roles of glutaminase-asparaginases and drug-induced cytoprotective autophagy mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI